Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:43:00.655Z.
Calculation as of: 2026-10-06T19:43:00.655Z.
Quote observation: 2026-10-06T19:40:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f06b8b41e0980caada53469fccf6de542fb6b04de3a821a907ddebd40a39f21
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$538.80M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProKidney Corp. (PROK) | $529.60M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $525.16M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $527.49M | N/A | 1.23% | 1.23% | 1.23% |
| Immix Biopharma, Inc. (IMMX)vs › | $528.79M | N/A | N/A | N/A | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $535.91M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $517.28M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $539.25M | N/A | N/A | N/A | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $538.80M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $513.26M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $510.23M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
